Immunovant R&D Day

March 30th, 2022


The virtual R&D Day highlighted Immunovant’s vision to enable normal lives for people with autoimmune diseases and provided insights into the broad potential of batoclimab, a novel, fully human monoclonal antibody designed to selectively bind to and inhibit the neonatal Fc receptor (FcRn), thus blocking the recycling of IgG antibodies. This event featured six key opinion leaders with expertise in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol management.